PSIL250117C10000
- 3.00
- 0.000.00%
ADVISORSHARES PSYCHEDELICS ETF Newsroom
J&J Beats in Q4 With in Line Guidance; so Why Is Its Stock Falling?
Intra-Cellular Ticks Higher as J&J Forecasts Early Q2 Close
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
NRx Pharmaceuticals Regains Compliance With Nasdaq Minimum Market Value Of Listed Securities Requirement
Top 4 Health Care Stocks You May Want To Dump In Q1
Trending Stocks as Wall Street Bounces Back With Strong Week
Catalyst Watch: Netflix Earnings, Monster Beverage Event, Drug Data, and Quantum Volatility
Watching Mind Medicine; Shares Moving Higher As Traders Circulate Stock Picked By Popular Newsletter Service
Compass Pathways Analyst Ratings
On the first day of the JPM Medical Conference, pharmaceutical giants are announcing new strategies. Could the mergers and acquisitions in Biomedical begin in 2025?
In 2025, the Biomedical mergers and acquisitions will begin.
Futu Morning Report | Major new regulations impact AI Chip stocks! NVIDIA and Oracle strongly oppose; Is there a bet that the yield has peaked? Call Bid in U.S. Treasury ETF surges.
Media: NVIDIA's Blackwell chip rack has encountered issues, leading major customers like Microsoft to reduce some Orders; Trump's advisers have proposed a new tariff idea: use the Emergency Economic Powers Act to increase rates by 2-5% monthly; the new US Treasury Secretary's Hold Positions include the S&P 500, Nasdaq, and Bitcoin.
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Sage Therapeutics Shares Are Trading Higher After the Company Confirmed the Receipt of an Unsolicited, Nonbinding Proposal From Biogen to Acquire All Outstanding Shares Not Already Owned by Biogen for $7.22 per Share.
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Intra-Cellular Therapies Analyst Ratings
Intra-Cellular surged nearly 35%! Johnson & Johnson plans to spend $10 billion to acquire the company, marking the largest Biotechnology merger in nearly two years!
This is the largest Trade in the biotechnology Industry in nearly two years, and it is also the first Biomedical merger exceeding 10 billion dollars since 2024, indicating a resurgence in merger and acquisition activities in the Medical Care sector. Goldman Sachs stated that the potential financing capacity of large Biopharmaceutical companies is at least 500 billion dollars, providing significant operational space for R&D investment, merger expansion, and more.
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?